{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T23:16:06Z","timestamp":1778541366033,"version":"3.51.4"},"reference-count":21,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100003819","name":"Natural Science Foundation of Hubei Province","doi-asserted-by":"publisher","award":["2022CFB142"],"award-info":[{"award-number":["2022CFB142"]}],"id":[{"id":"10.13039\/501100003819","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmaceutical and Biomedical Analysis"],"published-print":{"date-parts":[[2023,6]]},"DOI":"10.1016\/j.jpba.2023.115382","type":"journal-article","created":{"date-parts":[[2023,3,31]],"date-time":"2023-03-31T20:42:33Z","timestamp":1680295353000},"page":"115382","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Determination of olverembatinib in human plasma and cerebrospinal fluid by an LC-MS\/MS method: Validation and clinical application"],"prefix":"10.1016","volume":"230","author":[{"given":"Dong","family":"Xiang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tinghui","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jue","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yang","family":"Cao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qiuxia","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lu","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hengyi","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiping","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ninghong","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yang","family":"Yi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xuepeng","family":"Gong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jpba.2023.115382_bib1","doi-asserted-by":"crossref","first-page":"4820","DOI":"10.3390\/cancers13194820","article-title":"Resistance to tyrosine kinase inhibitors in chronic myeloid leukemia-from molecular mechanisms to clinical relevance","volume":"13","author":"Alves","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.jpba.2023.115382_bib2","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1016\/j.ccell.2020.03.006","article-title":"Response and resistance to BCR-ABL1-targeted therapies","volume":"37","author":"Braun","year":"2020","journal-title":"Cancer Cell"},{"key":"10.1016\/j.jpba.2023.115382_bib3","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1038\/s41375-020-0776-2","article-title":"European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia","volume":"34","author":"Hochhaus","year":"2020","journal-title":"Leukemia"},{"key":"10.1016\/j.jpba.2023.115382_bib4","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/s11912-021-01087-x","article-title":"Review of new-generation tyrosine kinase inhibitors for chronic myeloid leukemia","volume":"23","author":"Shoukier","year":"2021","journal-title":"Curr. Oncol. Rep."},{"key":"10.1016\/j.jpba.2023.115382_bib5","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1007\/s00277-020-03949-z","article-title":"T315I mutation exerts a dismal prognosis on adult BCR-ABL1-positive acute lymphoblastic leukemia, and salvage therapy with ponatinib or CAR-T cell and bridging to allogeneic hematopoietic stem cell transplantation can improve clinical outcomes","volume":"99","author":"Ting","year":"2020","journal-title":"Ann. Hematol."},{"key":"10.1016\/j.jpba.2023.115382_bib6","first-page":"1002","volume":"120","author":"Soverini","year":"2014","journal-title":"Cancer Am. Cancer Soc."},{"key":"10.1016\/j.jpba.2023.115382_bib7","doi-asserted-by":"crossref","first-page":"3598","DOI":"10.1182\/blood-2021-153937","article-title":"Updated results of pivotal phase 2 trials of olverembatinib (HQP1351) in patients (Pts) with tyrosine kinase inhibitor (TKI)-resistant BCR-ABL1 T315I-mutated chronic- and accelerated-phase chronic myeloid leukemia (CML-CP and CML-AP)","volume":"138","author":"Qian","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.jpba.2023.115382_bib8","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1021\/jm301581y","article-title":"Identification of GZD824 as an orally bioavailable inhibitor that targets phosphorylated and nonphosphorylated breakpoint cluster region-Abelson (Bcr-Abl) kinase and overcomes clinically acquired mutation-induced resistance against imatinib","volume":"56","author":"Ren","year":"2013","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.jpba.2023.115382_bib9","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1007\/s11899-021-00658-w","article-title":"Future directions in chronic phase CML treatment","volume":"16","author":"Javidi-Sharifi","year":"2021","journal-title":"Curr. Hematol. Malig. Rep."},{"key":"10.1016\/j.jpba.2023.115382_bib10","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1186\/s13045-022-01334-z","article-title":"Olverembatinib (HQP1351), a well-tolerated and effective tyrosine kinase inhibitor for patients with T315I-mutated chronic myeloid leukemia: results of an open-label, multicenter phase 1\/2 trial","volume":"15","author":"Jiang","year":"2022","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.jpba.2023.115382_bib11","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1007\/s40265-022-01680-9","article-title":"Olverembatinib: first approval","volume":"82","author":"Dhillon","year":"2022","journal-title":"Drugs"},{"key":"10.1016\/j.jpba.2023.115382_bib12","first-page":"137","author":"Tan","year":"2017","journal-title":"Nonspecific binding in LC-MS bioanalysis"},{"key":"10.1016\/j.jpba.2023.115382_bib13","first-page":"271","article-title":"Simultaneous determination of imatinib, dasatinib, nilotinib, voriconazole, itraconazole, and posaconazole concentration in plasma by LC-MS\/MS","volume":"2","author":"Dong","year":"2022","journal-title":"Chin. J. Pharm. Anal."},{"key":"10.1016\/j.jpba.2023.115382_bib14","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1093\/chromsci\/bmt037","article-title":"LC-MS-MS determination of imatinib and N-desmethyl imatinib in human plasma","volume":"52","author":"Zhang","year":"2014","journal-title":"J. Chromatogr. Sci."},{"key":"10.1016\/j.jpba.2023.115382_bib15","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.jchromb.2013.01.037","article-title":"Simultaneous analysis of anticancer agents bortezomib, imatinib, nilotinib, dasatinib, erlotinib, lapatinib, sorafenib, sunitinib and vandetanib in human plasma using LC\/MS\/MS","volume":"926","author":"Andriamanana","year":"2013","journal-title":"J. Chromatogr. B Anal. Technol. Biomed. Life Sci."},{"key":"10.1016\/j.jpba.2023.115382_bib16","article-title":"The development and validation of a novel LC-MS\/MS method for the quantification of cenicriviroc in human plasma and cerebrospinal fluid","volume":"34","author":"Dilly","year":"2020","journal-title":"Biomed. Chromatogr."},{"key":"10.1016\/j.jpba.2023.115382_bib17","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1016\/j.jpha.2022.05.003","article-title":"Simultaneous determination of LY3214996, abemaciclib, and M2 and M20 metabolites in human plasma, cerebrospinal fluid, and brain tumor by LC-MS\/MS","volume":"12","author":"Margaryan","year":"2022","journal-title":"J. Pharm. Anal."},{"key":"10.1016\/j.jpba.2023.115382_bib18","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.4155\/bio.10.114","article-title":"Challenges in urine bioanalytical assays: overcoming nonspecific binding","volume":"2","author":"Ji","year":"2010","journal-title":"Bioanalysis"},{"key":"10.1016\/j.jpba.2023.115382_bib19","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1007\/s00216-003-2267-5","article-title":"Determination of a flame retardant hydrolysis product in human urine by SPE and LC-MS. Comparison of molecularly imprinted solid-phase extraction with a mixed-mode anion exchanger","volume":"378","author":"Moller","year":"2004","journal-title":"Anal. Bioanal. Chem."},{"key":"10.1016\/j.jpba.2023.115382_bib20","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1080\/10408347.2020.1791041","article-title":"Challenges and strategies for quantification of drugs in the brain: current scenario and future advancement","volume":"52","author":"Pyaram","year":"2022","journal-title":"Crit. Rev. Anal. Chem."},{"key":"10.1016\/j.jpba.2023.115382_bib21","doi-asserted-by":"crossref","DOI":"10.3389\/fchem.2021.782131","article-title":"Sensitive LC-MS\/MS methods for amphotericin b analysis in cerebrospinal fluid, plasma, plasma ultrafiltrate, and urine: application to clinical pharmacokinetics","volume":"9","author":"Pippa","year":"2021","journal-title":"Front. Chem."}],"container-title":["Journal of Pharmaceutical and Biomedical Analysis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0731708523001516?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0731708523001516?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T22:45:22Z","timestamp":1778539522000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0731708523001516"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6]]},"references-count":21,"alternative-id":["S0731708523001516"],"URL":"https:\/\/doi.org\/10.1016\/j.jpba.2023.115382","relation":{},"ISSN":["0731-7085"],"issn-type":[{"value":"0731-7085","type":"print"}],"subject":[],"published":{"date-parts":[[2023,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Determination of olverembatinib in human plasma and cerebrospinal fluid by an LC-MS\/MS method: Validation and clinical application","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmaceutical and Biomedical Analysis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jpba.2023.115382","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"115382"}}